Sobi's Tryngolza Receives EMA Validation for sHTG Treatment Indication Extension Sobi's Tryngolza has gained EMA validation for treating severe hypertriglyceridemia, marking a significant milestone in addressing patient needs.

Sobi's Tryngolza Receives EMA Validation for sHTG Treatment Indication Extension #Sweden #Stockholm #Sobi #Olezarsen #Tryngolza

Tryngolza®: A Breakthrough Treatment Approved in the EU for FCS Patients Sobi and Ionis Pharmaceuticals celebrate the EU approval of Tryngolza® (olezarsen) for treating familial chylomicronemia syndrome. A new hope for patients.

Tryngolza®: A Breakthrough Treatment Approved in the EU for FCS Patients #None #Olezarsen #Tryngolza #FCS

Recommendation for TRYNGOLZA® (olezarsen) Approval for FCS in the EU Sobi and Ionis Pharmaceuticals announce a positive CHMP opinion for TRYNGOLZA in treating familial chylomicronemia syndrome in Europe, highlighting significant clinical trial results.

Recommendation for TRYNGOLZA® (olezarsen) Approval for FCS in the EU #Sweden #Stockholm #Sobi #Olezarsen #Tryngolza

Ionis wins FDA nod for triglyceride-lowering rare disease drug - Nature Biotechnology Nature Biotechnology - Ionis wins FDA nod for triglyceride-lowering rare disease drug

In Brief: The @fda.gov approves Ionis Pharmaceuticals’ triglyceride-lowering rare disease drug #Tryngolza www.nature.com/articles/s41...
rdcu.be/d6V0J

Ionis' TRYNGOLZA™ Achieves FDA Milestone as First Treatment Option for Familial Chylomicronemia Syndrome Ionis Pharmaceuticals has achieved a groundbreaking milestone with the FDA approval of TRYNGOLZA™ (olezarsen), marking the first-ever treatment for adults with familial chylomicronemia syndrome (FCS)....

www.linkedin.com/pulse/ionis-...

Ionis' TRYNGOLZA™ Achieves FDA Milestone as First Treatment Option for Familial Chylomicronemia Syndrome

kstrategyand.com/pharma-news

#IonisPharmaceuticals #TRYNGOLZA #GeneticDisorders #LifeChangingTreatment #Humanteconomy #Humantec

PANTHERx® Rare Collaborates with Ionis for TRYNGOLZA™ Distribution, a Milestone in Rare Disease Treatment PANTHERx® Rare has partnered with Ionis Pharmaceuticals to distribute TRYNGOLZA™, the first FDA-approved treatment for FCS, enhancing patient access.

PANTHERx® Rare Collaborates with Ionis for TRYNGOLZA™ Distribution, a Milestone in Rare Disease Treatment #United_States #Pittsburgh #Ionis_Pharmaceuticals #Tryngolza #PANTHERx_Rare

Highlights from the FDA: Key Updates and Approvals for December 2024 The FDA has made significant updates this December, including guidelines for clinical decision support software and new approvals for HIV self-tests and treatments.

Highlights from the FDA: Key Updates and Approvals for December 2024 #United_States #FDA #Silver_Spring #OraQuick #Tryngolza

FDA Approves RNA-targeted Therapy for Familial Chylomicronemia Syndrome Olezarsen@is the first approved treatment in the U.S. for FCS, which prevents the body from breaking down fats. The treatment is an@antisense oligonucleotide (ASO).

FDA approved #Tryngolza (also known as #Olezarsen), an investigational, first-in-class, RNA-targeted medicine for the treatment of adults with familial chylomicronemia syndrome (FCS). FCS is a rare genetic disease that prevents the body from breaking down fats. www.asgct.org/publications...